BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Beam Therapeutics Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Beam Therapeutics Inc.'s drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06735755-10772@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:BEAM-301: Phase 1/2 readout est. (NCT06735755)
DESCRIPTION:BEAM-301\, phase 1/2\, Glycogen Storage Disease Type Ia.\nStudy
 : A Phase 1/2\, Dose-Exploration Study to Evaluate the Safety and Efficacy
  of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)\nEs
 timated primary completion: 30 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/beam-301#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06735755
URL:https://assetmemo.bio/drug/beam-301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05456880-10266@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ristoglogene autogetemcel: Phase 1/2 readout est. (NCT05456880)
DESCRIPTION:Ristoglogene autogetemcel\, phase 1/2\, Sickle Cell Disease.\nS
 tudy: BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Pa
 tients With Severe Sickle Cell Disease\nEstimated primary completion: Febr
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ristogloge
 ne-autogetemcel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05456880
URL:https://assetmemo.bio/drug/ristoglogene-autogetemcel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389877-10771@assetmemo.bio
DTSTAMP:20261121T005014Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:BEAM-302: Phase 1/2 readout est. (NCT06389877)
DESCRIPTION:BEAM-302\, phase 1/2\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients 
 With Alpha-1 Antitrypsin Deficiency (AATD)\nEstimated primary completion: 
 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beam-302#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063898
 77
URL:https://assetmemo.bio/drug/beam-302#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
